Table III.

Least Square Mean Percentage Changes (+ Standard Error) From Baseline in Lipid Parameters of Entire Study Population (Risk Groups I, II, and III Combined)

		Double‐Blind Treatment Group*
Lipid Parameter	AML 5 mg+ ATV 10 mg	AML 5 mg	ATV 10 mg	Placebo	Single‐Blind, Open‐Label**
LDL‐C	−37.2±0.9†,††	−1.8±0.9	−33.9±0.9‡	0.2±0.8	−41.0±0.4
Patients (n)	201	193	193	229	687
Total cholesterol	−27.7±0.6‡‡††	−2.1±0.6	−24.4±0.6‡	−0.9±0.6	−31.0±0.4
Patients (n)	201	193	193	229	687
Triglycerides	−23.0*±2.2††	−2.3±2.3	−17.2±23‡	−0.1±2.1	−29.0±1.1
Patients (n)	201	193	193	229	687
HDL‐C	5.0±1.0††	0.0±1.0	4.1±1.0§	0.2±0.9	5.2±0.6
Patients (n)	201	193	193	229	687
Apolipoprotein B	−30.7±0.8§§††	−1.7±0.8	−27.9±0.8‡	−1.0±0.7	−34.5±0.4
Patients (n)	189	185	183	210	687
LDL‐C=low‐density lipoprotein cholesterol; HDL‐C=high‐density lipoprotein cholesterol; *from baseline to the end of the doubleblind phase (Week 8); **from baseline to the end of the open‐label phase (Week 28); † p=0.007 vs. atorvastatin alone; †† p<0.001 vs. amlodipine alone; ‡ p<0.001 vs. placebo; ‡‡ p<.001 vs. atorvastatin alone; § p=0.005 vs. placebo; §§ p=0.013 vs. atorvastatin alone